OUR HISTORY

First commercial 3D printing based on filament is commecialised by Stratasys Inc. It was called rapid prototyping.

On receiving news that Prof. Charles Vacanti was able to grow a ear on the back of a mouse, our founders embark on tissue engineering research and development.

Inventors from National University of Singapore, National University Hospital and Temasek Polytechnic initiated research to identify the bioresorbable material, microarchitecture and manufacturing technique.

First-in-human procedure with Osteopore technology. Osteopore (OSX)’s implant carried out in a top hat configuration as a burr hole cover.

After the success of the first-in-human procedure for burr hole cover in 2002 and six years working on the technology, the team founded the company, Osteopore (OSX) International Pte Ltd.

Prospective randomized clinical trial with Osteomesh for orbital floor reconstruction successfully completed.

The first-in-human reconstruction for craniosynostosis with Osteomesh. Researchers estimate that about 1 in every 2,500 babies is born with craniosynostosis in the United States.

The Osteopore (OSX) technology for craniofacial application received the US FDA 510(k) clearance. Osteopore started expanding to the US market.

First-in-human 3D printed patient specific implant with polycaprolactone-tricalcium phosphate (PCL-TCP) microarchitecture for mandibular reconstruction.

Osteopore (OSX) manufacturing for craniofacial application received ISO 13485 certification.

First-in-human patient specific implant with Osteoplug (plug and strip configuration) for craniotomy.

In 2009, Osteoplug and Osteomesh were CE approved for cranial burr hole cover and orbital floor reconstruction respectively.

First-in-human patient specific implant with PCL-TCP for cranioplasty.

Osteopore (OSX) completed the first clinical trial for socket preservation in dental surgery.

Osteopore (OSX) moved to a purpose-built medical technology hub, JTC MedTech Hub, to expand their production capabilities.

Longest tibia reconstruction with Osteopore (OSX) regenerative implant performed by Dr Michael Wagels and team at the Princess Alexandra Hospital, Brisbane, Australia. 3-year post-operation results shows tibia bone successfully regenerated.

First-in-human for skull base with Osteomesh.

First-in-human rhinoplasty with Osteomesh.

First mandible reconstruction with Osteomesh shaped tray to hold autologous bone grafts. Bony ingrowth and remodeling observed at 2 and 5 months postoperatively.

First customized Osteopore (OSX) implant for orbital floor reconstruction.

Osteopore IPO on the Australian Securities Exchange took place on 23 September 2019.

The first in-human for mandible reconstruction took place.

Osteopore (OSX) secures A$19M clinical-industrial partnership.

Osteopore (OSX) achieves milestone of 80,000 implants across all major continents.